WallStSmart

Medtronic PLC (MDT)vsNeogen Corporation (NEOG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 3976% more annual revenue ($35.48B vs $870.56M). MDT leads profitability with a 13.0% profit margin vs -69.9%. NEOG appears more attractively valued with a PEG of 0.66. MDT earns a higher WallStSmart Score of 61/100 (C+).

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9

NEOG

Hold

41

out of 100

Grade: D

Growth: 4.0Profit: 2.0Value: 7.7Quality: 5.3
Piotroski: 3/9Altman Z: 0.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued
NEOGUndervalued (+81.3%)

Margin of Safety

+81.3%

Fair Value

$57.56

Current Price

$8.90

$48.66 discount

UndervaluedFair: $57.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

NEOG2 strengths · Avg: 9.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

PEG RatioValuation
0.668/10

Growing faster than its price suggests

Areas to Watch

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

NEOG4 concerns · Avg: 2.5/10
Market CapQuality
$1.95B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-29.0%2/10

ROE of -29.0% — below average capital efficiency

Revenue GrowthGrowth
-4.4%2/10

Revenue declined 4.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : NEOG

The strongest argument for NEOG centers on Price/Book, PEG Ratio. PEG of 0.66 suggests the stock is reasonably priced for its growth.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Bear Case : NEOG

The primary concerns for NEOG are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

MDT profiles as a value stock while NEOG is a turnaround play — different risk/reward profiles.

NEOG carries more volatility with a beta of 1.84 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 41/100). NEOG offers better value entry with a 81.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Neogen Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Neogen Corporation, develops, manufactures and markets various products for food and animal safety worldwide. The company is headquartered in Lansing, Michigan.

Visit Website →

Want to dig deeper into these stocks?